Douglas J. Swirsky Sells 6,939 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CFO Douglas J. Swirsky sold 6,939 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total transaction of $22,066.02. Following the completion of the sale, the chief financial officer now owns 111,811 shares of the company's stock, valued at approximately $355,558.98. This trade represents a 5.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

MaxCyte Price Performance

MXCT traded up $0.06 during trading on Monday, reaching $3.15. 415,467 shares of the stock traded hands, compared to its average volume of 509,524. The stock's 50-day simple moving average is $4.04 and its two-hundred day simple moving average is $3.93. MaxCyte, Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $5.26. The stock has a market cap of $333.99 million, a price-to-earnings ratio of -9.26 and a beta of 1.35.

Institutional Investors Weigh In On MaxCyte

Several large investors have recently made changes to their positions in MXCT. Franklin Resources Inc. bought a new stake in MaxCyte in the third quarter worth approximately $260,000. Barclays PLC boosted its holdings in MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after purchasing an additional 127,156 shares in the last quarter. Geode Capital Management LLC boosted its holdings in MaxCyte by 2.0% in the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock worth $9,628,000 after purchasing an additional 47,960 shares in the last quarter. Mudita Advisors LLP increased its position in MaxCyte by 5.6% during the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company's stock worth $12,267,000 after buying an additional 167,101 shares during the last quarter. Finally, State Street Corp lifted its position in shares of MaxCyte by 5.1% in the third quarter. State Street Corp now owns 2,269,135 shares of the company's stock worth $8,827,000 after buying an additional 111,066 shares during the last quarter. Institutional investors own 68.81% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

MXCT has been the topic of several recent analyst reports. BTIG Research set a $6.00 price target on MaxCyte and gave the company a "buy" rating in a research report on Wednesday, March 12th. Stifel Nicolaus dropped their target price on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.